CVS Health Reports Strong Earnings, Optimistic 2026 Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 11 2026
0mins
Should l Buy CVS?
Source: Benzinga
- Strong Sales Performance: CVS Health reported sales of $105.69 billion, exceeding the market consensus of $103.59 billion, demonstrating robust performance in a competitive healthcare market and boosting investor confidence.
- Earnings Improvement: Adjusted earnings per share reached $1.09, surpassing analyst estimates of $0.99, although down from $1.19 a year ago, reflecting the company's efforts in cost control and operational efficiency.
- 2026 Financial Guidance: CVS reaffirmed its adjusted earnings guidance for 2026 at $7.00-$7.20 per share, slightly below the consensus of $7.17, indicating confidence in future growth despite facing market challenges.
- Cash Flow Adjustment: The company revised its cash flow from operations guidance down to at least $9.0 billion from a previous estimate of $10.0 billion, reflecting a cautious approach in the current economic environment while maintaining flexibility for future investments and growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CVS
Wall Street analysts forecast CVS stock price to rise
17 Analyst Rating
16 Buy
1 Hold
0 Sell
Strong Buy
Current: 78.010
Low
91.00
Averages
96.71
High
105.00
Current: 78.010
Low
91.00
Averages
96.71
High
105.00
About CVS
CVS Health Corporation is a health solutions company. The Company's segments include Health Care Benefits, Health Services, Pharmacy & Consumer Wellness and Corporate/Other. Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, PDPs and Medicaid health care management services. Health Services segment provides a full range of pharmacy benefit management (PBM) solutions through its CVS Caremark operations and delivers health care services in its medical clinics, virtually, and in the home. Pharmacy & Consumer Wellness segment dispenses prescriptions in its CVS Pharmacy retail locations and through its infusion operations, provides ancillary pharmacy services including pharmacy patient care programs, diagnostic testing and vaccination administration, and sells a wide assortment of health and wellness products and general merchandise.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Healthcare Sector Outlook: CVS and Vertex Prospects
- CVS Recovery: CVS Health's share price surged over 70% in 2025, and it is expected to maintain this growth momentum in 2026, despite plans to scale back its Medicare Advantage business to enhance long-term profitability, indicating a strategic shift towards sustainable growth.
- Strategic Focus: By exiting the Obamacare marketplace, CVS aims to concentrate on long-term profitability, which may not significantly impact short-term financial results but is likely to enhance its competitive position in the future.
- Vertex Drug Progress: Vertex Pharmaceuticals anticipates that its new drugs, Journavx and Casgevy, will generate at least $500 million in sales in 2026, which, while modest compared to its total revenue of $12 billion in 2025, highlights the potential for product line diversification.
- Clinical Advancements: Vertex plans to seek approval for its Type 1 diabetes drug, zimislecel, and will release phase 3 study data for treatments targeting IgA nephropathy and APOL-1 mediated kidney disease, further strengthening its market position and product portfolio.
See More
CVS Health and Vertex Pharmaceuticals Outlook
- CVS Health Strategic Shift: CVS Health plans to scale back its Medicare Advantage business in 2026, which may not significantly impact financial results in the short term but aims to enhance long-term profitability, thereby strengthening its leadership position in the healthcare sector.
- Stock Price Recovery: In 2025, CVS Health's share price soared over 70% due to improved financial results, laying a solid foundation for continued growth in 2026, reflecting the company's deep roots in the U.S. healthcare ecosystem and strong customer relationships.
- Vertex Pharmaceuticals New Product Progress: Vertex Pharmaceuticals expects its new products, Journavx and Casgevy, to generate at least $500 million in sales in 2026, which, while modest, will provide crucial support for the company's future revenue growth.
- Clinical and Regulatory Advances: Vertex plans to seek approval for its investigational medicine zimislecel for Type 1 diabetes in 2026 and release phase 3 study data for next-gen programs, further enhancing the diversity and competitiveness of its product lineup.
See More
Trump Administration Halts $259 Million Medicaid Funds to Minnesota
- Medicaid Funding Suspension: U.S. Vice President JD Vance announced the withholding of $259 million in Medicaid funds from Minnesota due to the state's failure to prevent the theft of federal funds, highlighting significant regulatory shortcomings in social welfare programs.
- State Government Pushback: Minnesota Governor Tim Walz retaliated on social media, accusing the Trump administration of attempting to punish states led by Democrats, illustrating the political tensions intertwined with healthcare policy.
- Audit Findings Impact: Medicaid program overseer Dr. Mehmet Oz stated that the payment halt follows audit findings, requiring Minnesota to propose a comprehensive corrective action plan within 60 days, emphasizing the stringent scrutiny of Medicaid fund usage.
- Nationwide Enrollment Pause: Additionally, a six-month nationwide pause on Medicaid enrollment for durable medical equipment suppliers was announced, aimed at addressing fraud risks among these providers, thereby intensifying oversight of the Medicaid system.
See More
Novo Nordisk Faces Market Pressures and Competition
- Market Share Decline: Despite being the first to launch a GLP-1 weight loss drug, Novo Nordisk's market share has fallen to about 40%, while rival Eli Lilly holds 60%, indicating a significant competitive disadvantage that could hinder future growth potential.
- Sales Forecast Downgrade: Novo Nordisk anticipates a 5% to 13% decline in sales and profits for 2026, marking the first annual sales drop since 2017, reflecting the company's vulnerability amid fierce competition and pricing pressures, which may further erode investor confidence.
- Drug Development Challenges: The disappointing trial results of Novo's next-generation weight loss drug CagriSema against Eli Lilly's Zepbound led to a more than 16% drop in stock price on the day of the announcement, significantly diminishing analysts' confidence in its commercial potential and possibly affecting future market performance.
- Increasing Pricing Pressure: The decline in GLP-1 drug prices in the U.S. is weighing on Novo Nordisk's revenue and profitability, especially since the U.S. market has accounted for over half of its total sales since 2023, making future pricing strategies critical for the company's ability to regain growth.
See More
Energy and Healthcare Stocks Underperform
- Energy Sector Decline: As of midday Tuesday, energy companies are down 0.4%, with ONEOK Inc (OKE) and EQT Corp (EQT) showing losses of 5.2% and 1.7%, respectively, indicating sector weakness that may impact investor confidence.
- ETF Performance Analysis: The Energy Select Sector SPDR ETF (XLE) is down 0.2% on the day but up 23.09% year-to-date, suggesting that despite short-term volatility, the long-term trend remains positive, potentially attracting more investor interest.
- Healthcare Sector Weakness: The healthcare sector is up 0.3% overall, yet Molina Healthcare Inc (MOH) and CVS Health Corporation (CVS) are down 4.2% and 3.7%, respectively, reflecting challenges faced by the sector that may influence future investment decisions.
- ETF Tracking Status: The Health Care Select Sector SPDR ETF (XLV) is down 0.3% on the day and up 2.09% year-to-date, showing some resilience despite short-term underperformance, which may provide investors with opportunities for risk diversification.
See More
Novo Nordisk Plans Major Price Cuts for Drugs
- Price Reduction Announcement: Novo Nordisk plans to cut the monthly list prices of its obesity and diabetes drugs by up to 50% starting in 2027, setting a new price of $675 per month to enhance accessibility for insured patients.
- Targeting Insured Patients: The price cuts specifically target insured patients whose out-of-pocket costs are linked to list prices, with commercial insurance patients potentially paying as little as $25 per month, thereby improving Novo's competitiveness in the GLP-1 market.
- Impact of Medicare Changes: This pricing strategy aligns with new Medicare prices set to take effect in 2027, where negotiated prices for Wegovy, Ozempic, and Rybelsus will be $274 per month, further alleviating patient costs.
- Industry Response: Novo's price reduction responds to market demands for lower drug prices, aiming to eliminate cost barriers and allow more patients to realize the benefits of Wegovy and Ozempic, while also reflecting the ongoing pricing competition with Eli Lilly.
See More
Healthcare Sector Outlook: CVS and Vertex Prospects
- CVS Recovery: CVS Health's share price surged over 70% in 2025, and it is expected to maintain this growth momentum in 2026, despite plans to scale back its Medicare Advantage business to enhance long-term profitability, indicating a strategic shift towards sustainable growth.
- Strategic Focus: By exiting the Obamacare marketplace, CVS aims to concentrate on long-term profitability, which may not significantly impact short-term financial results but is likely to enhance its competitive position in the future.
- Vertex Drug Progress: Vertex Pharmaceuticals anticipates that its new drugs, Journavx and Casgevy, will generate at least $500 million in sales in 2026, which, while modest compared to its total revenue of $12 billion in 2025, highlights the potential for product line diversification.
- Clinical Advancements: Vertex plans to seek approval for its Type 1 diabetes drug, zimislecel, and will release phase 3 study data for treatments targeting IgA nephropathy and APOL-1 mediated kidney disease, further strengthening its market position and product portfolio.
See More
CVS Health and Vertex Pharmaceuticals Outlook
- CVS Health Strategic Shift: CVS Health plans to scale back its Medicare Advantage business in 2026, which may not significantly impact financial results in the short term but aims to enhance long-term profitability, thereby strengthening its leadership position in the healthcare sector.
- Stock Price Recovery: In 2025, CVS Health's share price soared over 70% due to improved financial results, laying a solid foundation for continued growth in 2026, reflecting the company's deep roots in the U.S. healthcare ecosystem and strong customer relationships.
- Vertex Pharmaceuticals New Product Progress: Vertex Pharmaceuticals expects its new products, Journavx and Casgevy, to generate at least $500 million in sales in 2026, which, while modest, will provide crucial support for the company's future revenue growth.
- Clinical and Regulatory Advances: Vertex plans to seek approval for its investigational medicine zimislecel for Type 1 diabetes in 2026 and release phase 3 study data for next-gen programs, further enhancing the diversity and competitiveness of its product lineup.
See More
Trump Administration Halts $259 Million Medicaid Funds to Minnesota
- Medicaid Funding Suspension: U.S. Vice President JD Vance announced the withholding of $259 million in Medicaid funds from Minnesota due to the state's failure to prevent the theft of federal funds, highlighting significant regulatory shortcomings in social welfare programs.
- State Government Pushback: Minnesota Governor Tim Walz retaliated on social media, accusing the Trump administration of attempting to punish states led by Democrats, illustrating the political tensions intertwined with healthcare policy.
- Audit Findings Impact: Medicaid program overseer Dr. Mehmet Oz stated that the payment halt follows audit findings, requiring Minnesota to propose a comprehensive corrective action plan within 60 days, emphasizing the stringent scrutiny of Medicaid fund usage.
- Nationwide Enrollment Pause: Additionally, a six-month nationwide pause on Medicaid enrollment for durable medical equipment suppliers was announced, aimed at addressing fraud risks among these providers, thereby intensifying oversight of the Medicaid system.
See More
Novo Nordisk Faces Market Pressures and Competition
- Market Share Decline: Despite being the first to launch a GLP-1 weight loss drug, Novo Nordisk's market share has fallen to about 40%, while rival Eli Lilly holds 60%, indicating a significant competitive disadvantage that could hinder future growth potential.
- Sales Forecast Downgrade: Novo Nordisk anticipates a 5% to 13% decline in sales and profits for 2026, marking the first annual sales drop since 2017, reflecting the company's vulnerability amid fierce competition and pricing pressures, which may further erode investor confidence.
- Drug Development Challenges: The disappointing trial results of Novo's next-generation weight loss drug CagriSema against Eli Lilly's Zepbound led to a more than 16% drop in stock price on the day of the announcement, significantly diminishing analysts' confidence in its commercial potential and possibly affecting future market performance.
- Increasing Pricing Pressure: The decline in GLP-1 drug prices in the U.S. is weighing on Novo Nordisk's revenue and profitability, especially since the U.S. market has accounted for over half of its total sales since 2023, making future pricing strategies critical for the company's ability to regain growth.
See More
Energy and Healthcare Stocks Underperform
- Energy Sector Decline: As of midday Tuesday, energy companies are down 0.4%, with ONEOK Inc (OKE) and EQT Corp (EQT) showing losses of 5.2% and 1.7%, respectively, indicating sector weakness that may impact investor confidence.
- ETF Performance Analysis: The Energy Select Sector SPDR ETF (XLE) is down 0.2% on the day but up 23.09% year-to-date, suggesting that despite short-term volatility, the long-term trend remains positive, potentially attracting more investor interest.
- Healthcare Sector Weakness: The healthcare sector is up 0.3% overall, yet Molina Healthcare Inc (MOH) and CVS Health Corporation (CVS) are down 4.2% and 3.7%, respectively, reflecting challenges faced by the sector that may influence future investment decisions.
- ETF Tracking Status: The Health Care Select Sector SPDR ETF (XLV) is down 0.3% on the day and up 2.09% year-to-date, showing some resilience despite short-term underperformance, which may provide investors with opportunities for risk diversification.
See More
Novo Nordisk Plans Major Price Cuts for Drugs
- Price Reduction Announcement: Novo Nordisk plans to cut the monthly list prices of its obesity and diabetes drugs by up to 50% starting in 2027, setting a new price of $675 per month to enhance accessibility for insured patients.
- Targeting Insured Patients: The price cuts specifically target insured patients whose out-of-pocket costs are linked to list prices, with commercial insurance patients potentially paying as little as $25 per month, thereby improving Novo's competitiveness in the GLP-1 market.
- Impact of Medicare Changes: This pricing strategy aligns with new Medicare prices set to take effect in 2027, where negotiated prices for Wegovy, Ozempic, and Rybelsus will be $274 per month, further alleviating patient costs.
- Industry Response: Novo's price reduction responds to market demands for lower drug prices, aiming to eliminate cost barriers and allow more patients to realize the benefits of Wegovy and Ozempic, while also reflecting the ongoing pricing competition with Eli Lilly.
See More
